Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Current Deferred Revenue (2019 - 2020)

Opus Genetics has reported Current Deferred Revenue over the past 2 years, most recently at $650000.0 for Q3 2020.

  • Quarterly Current Deferred Revenue changed N/A to $650000.0 in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $650000.0 through Sep 2020, changed N/A year-over-year, with the annual reading at $1.5 million for FY2019, N/A changed from the prior year.
  • Current Deferred Revenue was $650000.0 for Q3 2020 at Opus Genetics, roughly flat from $650000.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $1.5 million in Q4 2019 and troughed at $600000.0 in Q1 2020.